por John R. Fischer
, Senior Reporter | November 20, 2023
iCardio.ai will work with Butterfly Network through its Butterfly Garden AI marketplace to develop its application for echocardiograph measurements and disease detection. (Photo courtesy of iCardio.ai)
Startup iCardio.ai has joined Butterfly Network’s artificial intelligence marketplace, Butterfly Garden, where it will develop and deploy its ultrasound imaging software alongside Butterfly iQ+, the first handheld, single-probe, whole-body ultrasound system using semiconductor technology and one transducer, for use among more than 100,000 healthcare providers.
iCardio.ai’s suite of tools automates critical measurements to compile preliminary echocardiographic reports, assesses image quality, and diagnoses valvular diseases such as aortic stenosis. It specifically is designed for transthoracic echocardiography and is trained on more than 200 million ultrasound scans.
Butterfly Network launched its AI marketplace in August 2023
to allow third-party developers like iCardio.ai to build and integrate new AI applications, using its proprietary software development kit (SDK) and applications program interfaces, into virtual care workflows. These solutions can be used alongside Butterfly iQ+.
“iCardio.ai’s complementary technology will not only bring additional capabilities to our Butterfly customers but also continue to make it easier for healthcare practitioners to use ultrasound wherever they may be,” said Darius Shahida, Butterfly Network’s chief strategy officer and chief business development officer, in a statement.
Butterfly Garden’s customer base is the largest for point-of-care ultrasound. Ultrasound AI company ThinkSono joined in October
and plans to build training solutions and ThinkSono Guidance, an algorithm software for identifying deep vein thrombosis (DVT) with Butterfly IQ+.
Through the program, Butterfly Network also established a five-year partnership in October with deep tech research company Forest Neurotech, which will incorporate the ultrasound-on-a-chip technology into a minimally invasive ultrasound device it is developing to be the first implanted, whole-brain neural interface
for providing personalized insights on neurological and psychiatric disorders to continuously update therapeutic regimens.
Among the measurements that iCardio.ai’s suite of algorithms can record are automated ejection fraction, feature extraction and navigation, and left ventricular outflow tract and aortic diameters.
“Our ambition aims to eventually put into the hands of every person with a Butterfly device the power of a superhuman AI cardiologist,” said Joseph Sokol, CEO and founder of iCardio.ai.
iCardio.ai’s software is pending FDA 510(k) clearance.